Hand Allotransplantation
Authors:
- 1 February 2010
- journal article
- Published by Georg Thieme Verlag KG in Seminars in Plastic Surgery
- Vol. 24 (01) , 011-017
Abstract
In the past decade, more than 100 different composite tissue allotransplantation (CTA) procedures have been performed around the world including more than 50 hand and 8 facial transplants with encouraging graft survival and excellent functional outcomes. Broader clinical application of CTA, however, continues to be hampered by requirement for long-term, high-dose, multidrug maintenance immunosuppression to prevent graft rejection mediated particularly by composite tissue allograft's highly immunogenic skin component. Medication toxicity could result in severe adverse events including metabolic and infectious complications or malignancy. Notably, unlike in solid organs, clinical success is dictated not only by graft acceptance and survival but also by nerve regeneration, which determines ultimate functional outcomes. Novel strategies such as cellular and biologic therapies that integrate the concepts of immune regulation with those of nerve regeneration have shown promising results in small and large animal models. Clinical translation of these insights to reconstructive transplantation and CTA could further minimize the need of immunosuppression and optimize functional outcomes. This will enable wider application of such treatment options for patients in need of complex reconstructive surgery for congenital deformities or devastating injuries that are not amenable to standard methods of repair.Keywords
This publication has 55 references indexed in Scilit:
- Mesenchymal Stem Cells Prolong Composite Tissue Allotransplant Survival in a Swine ModelTransplantation, 2009
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionNew England Journal of Medicine, 2008
- Second Report (1998–2006) of the International Registry of Hand and Composite Tissue TransplantationTransplant Immunology, 2007
- Tissue Engineering for the Hand Surgeon: A Clinical PerspectiveThe Journal of Hand Surgery, 2006
- Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradationBlood, 2004
- HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cellsExperimental Hematology, 2003
- Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cellsNeuroscience Letters, 2002
- Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivoExperimental Hematology, 2002
- Donor-specific tolerance induction in composite tissue allograftsThe American Journal of Surgery, 1998
- Cosmas and Damian in the LaboratoryNew England Journal of Medicine, 1982